Table 1 Changes in the patient’s rTMS application, CRS-R score, upper ARAS status, and medications
Duration from onset (months) | 5 months | → rTMS | 7 months | → No rTMS | 9 months | → rTMS | 10 months |
|---|---|---|---|---|---|---|---|
CRS-R | 4 | Â | 13 | Â | 13 | Â | 13 (higher cognition: improved) |
Change of upper ARAS |  | Rt prefrontal lobe ↑ |  | Rt prefrontal lobe ↓ |  | Rt prefrontal lobe ↑ |  |
Drugs |  | levodopa 750 mg, amantadine 200 mg, bromocriptine 10 mg, zolpidem 10 mg, baclofen 75 mg |  | levodopa 500 mg, amantadine 150 mg, bromocriptine 3.75 mg |  | levodopa 500 mg, amantadine 150 mg, bromocriptine 3.75 mg |  |